In Raji and K562/CD19 cells, OVV-CD19BiTE treatment elicited significantly increased cell death (p < 0.001 for Raji and K562/CD19) compared with blinatumomab treatment (Fig. 3D), demonstrated superior in vitro CD19+ tumor cytotoxicity. Here, CD19 is linked to neoplasm.